Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab for recurrent MOG antibody-positive optic neuritis
ChiCTR2500100442Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of secukinumab in optic neuritis (ON), sponsored by Chinese PLA General Hospital. Primary endpoint: Interval between disease relapses. Started Apr 2025; status: recruiting.
02
Drugs
secukinumab
03
Conditions
optic neuritis (ON)
Beyond the preview
Go deeper on ChiCTR2500100442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100442.